Zydus Cadila Signs Pact With Gilead To Make Remdesivir

Drugmaker Zydus Cadila said on Friday it signed a non-exclusive agreement with Gilead Sciences Inc to manufacture and market antiviral drug remdesivir, the first treatment to show improvement in COVID-19 trials.

Unlock this article for free
Sign up to access exclusive stories, fewer ads, and a personalised experience.
Set as Trusted Source
on Google Search